NDV-01
Non-Muscle Invasive Bladder Cancer (NMIBC)
Key Facts
About Relmada Therapeutics
Relmada Therapeutics is executing a capital-efficient, late-stage development strategy with a focused pipeline targeting high-need areas in oncology and CNS. Its lead asset, NDV-01, has demonstrated a 90% overall response rate in a Phase 2a trial for non-muscular invasive bladder cancer (NMIBC), with a Phase 3 trial planned for H1 2026. Backed by an experienced leadership team and strengthened by a recent $160 million private placement, Relmada is positioned to reach key clinical milestones for NDV-01 and its CNS candidate, sepranolone, in Prader-Willi syndrome.
View full company profileAbout Relmada Therapeutics
Relmada Therapeutics is executing a capital-efficient, late-stage development strategy with a focused pipeline targeting high-need areas in oncology and CNS. Its lead asset, NDV-01, has demonstrated a 90% overall response rate in a Phase 2a trial for non-muscular invasive bladder cancer (NMIBC), with a Phase 3 trial planned for H1 2026. Backed by an experienced leadership team and strengthened by a recent $160 million private placement, Relmada is positioned to reach key clinical milestones for NDV-01 and its CNS candidate, sepranolone, in Prader-Willi syndrome.
View full company profileTherapeutic Areas
Other Non-Muscle Invasive Bladder Cancer (NMIBC) Drugs
| Drug | Company | Phase |
|---|---|---|
| FL115 | Forlong Biotechnology | Phase 2 |
| Fosciclopirox (Ciclopirox Prodrug) | CicloMed | Pre-clinical/Phase 1 |
| Vesique® (APL-1202) | Asieris Pharmaceuticals | Phase 3 |
| DPX-formulated Products | BioVaxys | Phase 1 |
| Alpha1H | Hamlet Biopharma | Phase 2 |
| LiPax | LIPAC Oncology | Phase 2 |
| VAX014 | Vaxiion Therapeutics | Phase 1/2 |
| ZH9 | Prokarium | Phase 1 |
| Dabogratinib (Onc) | Tyra Biosciences | Phase 1/2 |
| VDC Platform | Aura Biosciences | Preclinical |